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Abstract
Objective—This study examined the individual and combined impact of N-terminal pro-B-type 
natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), interleukin-6 
(IL-6), and high-sensitivity C-reactive protein (hs-CRP) on the prediction of heart failure 
incidence or progression in patients with type 2 diabetes.
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Research Design and Methods—A nested case-cohort study was conducted in 3,098 
participants with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Results—A higher value of each biomarker was significantly associated with a higher risk of 
heart failure incidence or progression, after adjustment for major risk factors. The hazard ratios per 
1-SD increase were 3.06 (95% CI 2.37-3.96) for NT-proBNP, 1.50 (1.27-1.77) for hs-cTnT, 1.48 
(1.27-1.72) for IL-6, and 1.32 (1.12-1.55) for hs-CRP. Addition of NT-proBNP to the model 
including conventional risk factors meaningfully improved 5-year risk predictive performance (c-
statistic 0.8162 to 0.8800; continuous net reclassification improvement [NRI] 73.1%; categorical 
NRI [<5%, 5-10%, >10% 5-year risk] 24.2%). In contrast, addition of hs-cTnT, IL-6 or hs-CRP 
did not improve the prediction metrics consistently either in combination or when added to NT-
proBNP.
Conclusions—Only NT-proBNP, strongly and consistently improved prediction of heart failure 
in patients with type 2 diabetes beyond a wide range of clinical risk factors and biomarkers.
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The number of people with heart failure has been increasing, most likely the result of ageing 
and the increasing prevalence of hypertension, diabetes, obesity and atherosclerotic disease 
(1). Heart failure increases mortality, hospitalization and decreases health-related quality of 
life and functional status, and also results in increasing medical costs (1). Therefore, 
prevention and management of heart failure is an important global public health problem.
Diabetes is one of the major risk factors for heart failure, being associated with over 50% 
increase in risk (2), and has strong adverse effects on the prognosis of heart failure (3). Heart 
failure has also been noted to be the second most common first presentation of CVD in 
patients with type 2 diabetes, and more common than myocardial infarction (2). Yet 
insufficient emphasis has been placed on the prevention and treatment of heart failure in the 
clinical management of diabetes (4).
Recently, several circulating biomarkers, such as C-reactive protein (CRP) (5), interleukin-6 
(IL-6) (6), N-terminal pro-B-type natriuretic peptide (NT-proBNP) (7,8), and high-
sensitivity cardiac troponin T (hs-cTnT) (9), have been shown to be associated with the 
incidence of CVD. It has also been suggested that these biomarkers may be useful in 
predicting the risk of heart failure. However, few studies have examined the association 
between these biomarkers and the risk of heart failure in patients with diabetes, and it is 
uncertain how well these biomarkers can classify the risk of heart failure in such patients. 
Given limited medical resources and costs, efficient identification of high risk patients for 
subsequent precise evaluation and intervention is crucial.
The objective of the present study was thus to examine the association of circulating cardiac 
stress (NT-proBNP for myocardial stretch and volume overload and hs-cTnT for myocardial 
damage) and inflammatory (high-sensitivity C-reactive protein [hs-CRP] and IL-6) markers 
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with the risk of heart failure and their additional risk predictive ability beyond that from 
traditional clinical risk factors in patients with type 2 diabetes.
Research Design and Methods
Study sample
We conducted a nested case-cohort study to examine the association between cardiac stress 
biomarkers and inflammatory markers and heart failure in patients with type 2 diabetes who 
participated in Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified 
Release Controlled Evaluation (ADVANCE) study (ClinicalTrials.gov number 
NCT00145925). The design and results of ADVANCE have been published in detail 
previously (10–12). Briefly, 11,140 patients with type 2 diabetes at high risk of 
cardiovascular events were enrolled from 215 centers in 20 countries, and randomly 
assigned to either a gliclazide (modified release)-based intensive glucose control strategy 
(target HbA1c ≤6.5 %) or standard glucose control strategy based on local guidelines and to 
either a fixed-dose combination of perindopril (4 mg) and indapamide (1.25 mg) or 
matching placebo, after a 6-week active run-in period. Approval for the study was obtained 
from each center’s institutional review board. All participants provided written informed 
consent.
Baseline data included demographic and clinical information. Weight, height, blood 
pressure, hemoglobin A1c (HbA1c), fasting lipid levels, urinary albumin-to-creatinine ratio 
(ACR) and serum creatinine were measured. The estimated glomerular filtration rate (eGFR) 
was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation 
(13). Twelve-lead electrocardiograms (ECGs) were obtained at baseline for the presence of 
atrial fibrillation, left ventricular hypertrophy, and pathological Q-waves. Atrial fibrillation 
was considered present when it was identified by the investigator on the baseline ECG or 
when atrial fibrillation confirmed by ECG had been previously diagnosed.
Plasma samples were obtained from all study participants at baseline and stored at -80°C for 
a median of 7.8 years. Samples were available from all countries involved in ADVANCE, 
except China and India, giving a total population of 7,376. For the nested case-cohort study 
(14), a random subcohort of 3,500 participants was selected from this base population, plus 
131 additional participants who had experienced a heart failure event during 5-year follow-
up (Supplemental Figure 1).
High-sensitivity IL-6 levels was assayed by ELISA (R&D Systems, Oxford, U.K.) and high-
sensitivity CRP by immunonephelometry (ProSpec; Dade Behring, Milton Keynes, U.K.) 
(15). NT-proBNP and hs-cTnT were assayed by electrochemiluminescence immunoassays 
performed on a Roche Elecsys 2010 automated platform (Roche Diagnostics, Burgess Hill, 
U.K.) (16,17). A detailed description of the measurement of stored samples has been 
published previously (15–17).
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Study Outcome
In this project, the study outcome was incidence or progression of heart failure (death due to 
heart failure, hospitalization due to heart failure, or worsening New York Heart Association 
class).
Statistical analysis
Categorical data are presented as number (percentage) and continuous data as mean (SD), 
where approximately symmetrically distributed, or median (interquartile range), where 
skewed. Differences in the mean values or proportions of the baseline characteristics of the 
patients according to outcome status were tested by chi-square test, unpaired t-test or 
Wilcoxon test, as appropriate. Hazard ratios (HRs) for incidence or progression of heart 
failure were calculated by weighted Cox regression models for case-cohort analyses using 
groups defined by the fifths and for a one standard deviation (SD) increase in each of IL-6, 
hs-CRP, hs-cTnT, and NT-proBNP, after log transformation. Three models, with different 
potential confounding variables, were fitted for each biomarker-heart failure combination: 
model 1 with age, sex, randomized blood pressure-lowering intervention, and randomized 
glucose control intervention; model 2 with, additionally, duration of diabetes mellitus, 
current smoking, history of myocardial infarction, history of hospitalization for heart failure, 
BMI, systolic blood pressure, heart rate, current or previous atrial fibrillation, pathological 
Q-wave on ECG, left ventricular hypertrophy on ECG, aspirin or other antiplatelet agent 
use, β-blocker use, calcium-channel blocker use, diuretics use, angiotensin-converting 
enzyme inhibitors or angiotensin II receptor blockers use, total cholesterol, HDL cholesterol, 
triglyceride, statin or other lipid-lowering agent, HbA1c, thiazolidinedione use, insulin use, 
urinary ACR and eGFR; and model 3 with, additionally to model 2, the other three 
biomarkers. Pre-defined subgroup analyses, using model 2, were performed by baseline 
history of heart failure, history of myocardial infarction, sex, age (split at its median), and 
duration of diabetes (also split at its median).
Prediction metrics for heart failure were calculated in the random subcohort. Discrimination 
was evaluated by c statistics for 5-year risk, accounting for censoring (18), and compared 
between model 2 and model 2 plus each biomarker individually and in combination. In 
addition, the ability of each biomarker to better classify the 5-year risk for incidence or 
progression of heart failure, compared to model 2, was evaluated by the integrated 
discrimination index (IDI) and the net reclassification improvement (NRI), using methods 
suitable for survival data (14). NRI was calculated by a continuous model for changes in risk 
classification and a categorical model based on <5%, 5-10%, and >10% 5-year risk.
In addition, sensitivity analyses were conducted after excluding 1) patients with a history of 
hospitalization for heart failure (n = 136) and 2) patients with NT-proBNP levels >400 
pg/mL (n = 391). All analyses were performed using SAS Enterprise Guide 7.11 (SAS 
Institute Inc., Cary, NC) or Stata software (release 13; StataCorp, College Station, TX, 
USA). A two-sided P <0.05 was considered to be statistically significant in all analyses.
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Results
A total of 3,631 patients comprised the entire case-cohort study. After a number of 
exclusions, shown in Supplemental Figure 1 (283 patients with insufficient stored plasma for 
measurement of biomarkers and 250 with missing values for covariates), the remaining 
3,098 patients were included in the present analysis. During a median follow-up of 5.0 years, 
237 experienced a heart failure event. Table 1 shows the baseline characteristics of study 
participants. 40% of the cohort was female, and the mean age was 67 years. IL-6, hs-CRP, 
hs-cTnT and NT-proBNP levels were significantly higher in patients who experienced a 
heart failure event.
The HRs and 95% CIs for heart failure according to fifths of each biomarker are depicted in 
Figure 1. The risk of heart failure increased significantly with increasing levels of all the 
biomarkers after adjustment for age, sex, randomized blood pressure-lowering and glucose 
control interventions, and clinical risk factors (all P for trend <0.01 in model 2). 
Multivariable-adjusted HRs (95% CIs) for the highest fifths compared with the lowest fifths 
were 2.62 (1.48-4.63) for IL-6, 2.22 (1.33-3.72) for hs-CRP, 2.70 (1.68-4.34) for hs-cTnT, 
and 12.53 (5.41-29.02) for NT-proBNP. Figure 2 shows the HRs and 95% CIs for heart 
failure according to a 1 SD increment in each biomarker. Higher values of all four 
biomarkers were significantly associated with higher risk of heart failure after adjusting for 
clinical risk factors (Model 2, all P <0.001). After further adjustment for the other 
biomarkers (Model 3), associations were attenuated and became non-significant for hs-CRP 
and hs-cTnT. In all adjustment sets, NT-proBNP showed the strongest association with heart 
failure (HR 2.77 [95% CI 2.12-3.63] in model 3). Broadly similar findings were observed in 
the sensitivity analyses after excluding patients with past history of hospitalization for heart 
failure (Supplemental Figure 2) or those with NT-proBNP levels >400 pg/mL (Supplemental 
Figure 3), though the associations were slightly attenuated when patients with NT-proBNP 
levels >400 pg/mL were excluded. There was no evidence of effect modification in the 
association between heart failure and NT-proBNP by sex, age, duration of diabetes, or 
history of hospitalization for heart failure (model 2, Supplemental Figure 4). Although 
significant heterogeneity (P = 0.004) was observed in the association in those with 
(HR=2.28 [95% CI 1.08-4.81]) and without (HR=3.52 [95% CI 2.66-4.66]) a history of 
myocardial infarction, the direction of the association was the same in both groups.
Addition of NT-proBNP to a model including conventional risk factors (model 2) greatly 
improved discrimination and classification of the 5-year risk of heart failure (c-statistic: 
0.8162 to 0.8800, P <0.001; IDI: 0.107, P <0.001; continuous NRI: 0.731, P <0.001, 
categorical NRI: 0.242, P <0.001) (Table 3). On the other hand, when any of IL-6, hs-CRP, 
or hs-cTnT was added to model 2, the improvements were not uniformly significant. NT-
proBNP alone showed comparable predictive ability compared with a comprehensive set of 
conventional risk factors (c-statistic: 0.8239 vs. 0.8162, P = 0.74).
Addition of NT-proBNP to model 2 plus IL-6, hs-CRP, and hs-cTnT significantly improved 
the c-statistic (0.8384 to 0.8816, P <0.001) and classification of outcomes (IDI: 0.081, P 
<0.001; continuous NRI: 0.664, P <0.001; categorical NRI: 0.191, P <0.001). On the other 
hand, addition of a combination of IL-6, hs-CRP, and hs-cTnT to model 2 plus NT-proBNP 
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improved classification (IDI: 0.029, P = 0.002; continuous NRI: 0.304, P = 0.002; 
categorical NRI: 0.010, P = 0.56), but did not improve discrimination (c-statistic: 0.8800 to 
0.8816, P = 0.65). Almost identical results were obtained when patients with past history of 
hospitalization for heart failure or those with NT-proBNP levels >400 pg/mL were excluded 
(Supplemental Tables 1 and 2).
Conclusions
To the best of our knowledge, this is the first study to examine the improvement in the risk 
predictive ability for future heart failure by adding biomarkers to conventional risk factors in 
patients with type 2 diabetes, using a comprehensive set of prediction metrics. Higher values 
of IL-6, hs-CRP, hs-cTnT, and NT-proBNP were significantly associated with a higher risk 
of incidence or progression of heart failure in patients with type 2 diabetes. These 
associations persisted after adjusting for a comprehensive set of conventional CVD risk 
factors. In addition, incorporation of NT-proBNP into a prediction model greatly improved 
discrimination and classification of the 5-year risk of heart failure beyond conventional use 
of risk factors. In contrast, none of IL-6, hs-CRP, and hs-cTnT provided clinically useful 
incremental information. These data were broadly similar in those with no previous history 
of heart failure hospitalization and when those with NT-proBNP levels >400 pg/mL were 
excluded.
A number of studies have reported that the usefulness of newly identified biomarkers such as 
NT-proBNP, hs-cTnT, hs-CRP, and IL-6 to predict incident heart failure (19,20). However, 
few studies have investigated prognostic ability for heart failure in patients with diabetes. A 
sub-analysis of the Steno-2 study found that NT-proBNP levels above the median of the 
study population were associated with an increased risk of a composite of cardiovascular 
mortality and hospitalization for congestive heart failure in 160 microalbuminuric patients 
with type 2 diabetes (21). Another observational study from the SAVOR-TIMI 53 
randomized trial, among 12,301 patients with type 2 diabetes, also showed a stepwise 
increased risk of hospitalization for heart failure with increasing levels of NT-proBNP, with 
no evidence of heterogeneity among those taking saxagliptin treatment or placebo (22). The 
addition of NT-proBNP to the model with clinical variables increased the c-statistic from 
0.81 to 0.85 (22). The present study adds to these prior studies by providing evidence that 
NT-proBNP considerably improved risk prediction for heart failure beyond that derived from 
a wide range of clinical risk factors, using a comprehensive set of discrimination and 
reclassification metrics. Addition of NT-proBNP to the model with clinical risk factors 
increased the c-statistic and improved IDI, continuous NRI, and categorical NRI. These 
findings suggest that assessment of NT-proBNP will help to identify those at high risk who 
should go on to further investigation, such as undergoing an echocardiogram, and 
intervention.
There is only one prior study examining the association between CRP and heart failure in 
patients with diabetes, and none examining associations for IL-6 and hs-cTnT. In a subgroup 
analysis from the Strong Heart Study, elevated CRP levels were associated with incident 
heart failure in American Indians with diabetes (23). Our findings are consistent and extend 
to patients with diabetes from a range of countries across Australasia, Europe and North 
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America. In addition, our study adds new information on the relationship between the risk of 
heart failure and IL-6 and hs-cTnT levels, with findings showing an elevated risk of heart 
failure with increasing levels in these markers but no improvements in prediction metrics 
when added to a model with traditional clinical risk factors.
Only addition of NT-proBNP to the model with clinical risk factors and the other three 
biomarkers strongly improved prognostic ability. On the other hand, addition of a 
combination of IL-6, hs-CRP and hs-cTnT to the model with clinical risk factors and NT-
proBNP had no such benefit. This suggests that NT-proBNP adds to predictive capacity for 
the incidence of heart failure and could be added to routine assessment of the risk.
Recently, the EMPAREG-REG OUTCOME trial reported that patients with type 2 diabetes 
who received empagliflozin, an inhibitor of sodium-glucose cotransporter 2, had a 
significantly lower risk of hospitalization for heart failure than those in the placebo group 
(24). This association may be partly driven by osmotic diuresis and changes in plasma 
volume and sodium excretion with modulation of the cardio-renal axis mediated by 
empagliflozin (25,26). NT-proBNP is a cardiac hormone secreted by cardiac myocytes in 
response to ventricular wall stresses secondary to volume and pressure overload (27). Thus 
risk prediction for heart failure using NT-proBNP could more accurately identify those 
patients who may benefit most from this kind of drug. Future interventional studies are 
required to ascertain the utility of this possible strategy.
The strengths of the present study include its large sample size, international recruitment in a 
well-characterized trial population, which was closely monitored and treated uniformly, 
completeness of follow-up, and adjustment for a variety of risk factors. In addition, this is 
the first study to examine the additional predictive ability of biomarkers beyond 
conventional risk factors, using a comprehensive range of prediction statistics, in patients 
with type 2 diabetes. Some limitations of our study should be discussed. First, a single 
measurement of levels of biomarkers may not accurately represent the true status of the 
participants. However, this would bias our results toward the null hypothesis of no 
association. Therefore, the true association may be stronger than that observed in the present 
study. Second, the participants in this study were those eligible for the clinical trial. 
Therefore, applicability of the present findings to the general populations of patients with 
diabetes may not be justified, although the characteristics of the ADVANCE cohort of 
baseline were similar to those reported by a number of community based epidemiological 
studies (28). Finally, there may be other possible confounders besides those used in the 
current study, leading to bias by residual confounding.
In conclusion, we found that IL-6, hs-CRP, hs-cTnT, and NT-proBNP were independent 
predictors of incidence of heart failure in patients with type 2 diabetes. However, only the 
addition of NT-proBNP materially improved the predictive performance for heart failure 
beyond that from conventional clinical risk factors. Further studies are needed to validate our 
findings.
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Abbreviations
ACR albumin-to-creatinine ratio
ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified 
Release Controlled Evaluation
ECG electrocardiogram
eGFR estimated glomerular filtration rate
HR hazard ratio
HbA1c hemoglobin A1c
hs-CRP high-sensitivity C-reactive protein
hs-cTnT high-sensitivity cardiac troponin T
IDI integrated discrimination index
IL-6 interleukin-6
NRI net reclassification improvement
NT-proBNP N-terminal pro-B-type natriuretic peptide
SD standard deviation
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Figure 1. Adjusted hazard ratios and 95% CIs for heart failure according to fifths of the 
biomarker.
Abbreviations: hs-CRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac 
troponin T; IL-6, interleukin-6; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Each biomarker was categorized into 5 groups according to the fifths. The ranges of IL-6 
were 0.19-1.48, 1.49-1.95, 1.96-2.58, 2.59-3.68, and 3.69-16.13 pg/mL. The ranges of hs-
CRP were 0.08-0.73, 0.74-1.33, 1.34-2.45, 2.46-4.75, and 4.78-130.00 mg/L. The ranges of 
hs-cTnT were 1.5, 3.0, 4.0-6.0, 7.0-12.0, and 13.0-751.0 ng/L. The ranges of NT-proBNP 
were 2.5-24.0, 25.0-59.0, 60.0-116.0, 117.0-255.0, and 256.0-35000.0 pg/mL.
Hazard ratios were adjusted for age, sex, randomised blood pressure-lowering intervention, 
randomised glucose control intervention, duration of diabetes mellitus, current smoking, 
history of myocardial infarction, history of hospitalization for heart failure, BMI, systolic 
blood pressure, heart rate, current or previous atrial fibrillation, pathological Q-wave on 
ECG, left ventricular hypertrophy on ECG, aspirin or other antiplatelet agent use, β-blocker 
use, calcium-channel blocker use, diuretics use, angiotensin-converting enzyme inhibitors or 
angiotensin II receptor blockers use, total cholesterol, HDL cholesterol, triglyceride, statin 
or other lipid-lowering agent, hemoglobin A1c, thiazolidinedione use, insulin use, urinary 
albumin-creatinine ratio, and estimated glomerular filtration rate.
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Figure 2. Adjusted hazard ratios and 95% CIs for heart failure according to a one standard 
deviation increment in the biomarker.
Abbreviations: ECG, electrocardiogram; HR, hazard ratio; hs-CRP, high-sensitivity C-
reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; IL-6, interleukin-6; NT-
proBNP, N-terminal pro-B-type natriuretic peptide; SD, standard deviation.
Model 1 was adjusted for age, sex, randomised blood pressure-lowering intervention, and 
randomised glucose control intervention.
Model 2 was additionally adjusted for duration of diabetes mellitus, current smoking, history 
of myocardial infarction, history of hospitalization for heart failure, BMI, systolic blood 
pressure, heart rate, current or previous atrial fibrillation, pathological Q-wave on ECG, left 
ventricular hypertrophy on ECG, aspirin or other antiplatelet agent use, β-blocker use, 
calcium-channel blocker use, diuretics use, angiotensin-converting enzyme inhibitors or 
angiotensin II receptor blockers use, total cholesterol, HDL cholesterol, triglyceride, statin 
or other lipid-lowering agent, hemoglobin A1c, thiazolidinedione use, insulin use, urinary 
albumin-creatinine ratio, and estimated glomerular filtration rate.
Model 3 was additionally adjusted for the other biomarkers.
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Table 1
Baseline characteristics according to outcome status
Heart failure event Overall
Variables
Yes
n=237
No
n=2,861 n=3,098
 Female (%) 83 (35) 1,162 (41) 1,245 (40)
 Age (years) 70 (7)* 66 (7) 67 (7)
 Duration of diabetes mellitus (years) 10.0 (7.6)* 7.5 (6.2) 7.7 (6.3)
 Current smoking (%) 30 (13) 426 (15) 456 (15)
 History of myocardial infarction (%) 61 (26)* 98 (3) 159 (5)
 History of hospitalization for heart failure (%) 38 (16)* 98 (3) 136 (4)
 BMI (kg/m2) 30.7 (5.6) 30.0 (5.2) 30.0 (5.2)
 SBP (mmHg) 149 (23) 147 (21) 147 (21)
 DBP (mmHg) 80 (12)* 82 (11) 82 (11)
 Heart rate (bpm) 74 (13) 73 (12) 73 (12)
 Current or previous atrial fibrillation (%) 49 (21)* 275 (10) 324 (10)
 Pathological Q-wave on ECG (%) 51 (22)* 307 (11) 358 (12)
 LVH on ECG (%) 37 (16)* 222 (8) 259 (8)
 Aspirin or other antiplatelet agent (%) 143 (60)* 1,378 (48) 1,521 (49)
 β-blocker (%) 71 (30) 856 (30) 927 (30)
 Calcium-channel blocker (%) 106 (45)* 815 (28) 921 (30)
 Diuretics ¶ (%) 119 (50)* 823 (29) 942 (30)
 ACE inhibitors ¶ or ARB (%) 175 (74)* 1,628 (57) 1,803 (58)
 Total cholesterol (mmol/l) 5.03 (1.13) 5.16 (1.17) 5.15 (1.17)
 HDL cholesterol (mmol/l) 1.17 (0.28)* 1.23 (0.33) 1.23 (0.33)
 Triglyceride (mmol/l) 1.60 (1.2 2, 2.30) 1.70 (1.2 0, 2.34) 1.70 (1.2 0, 2.33)
 Statin or other cholesterol-lowering agent (%) 101 (43) 1,265 (44) 1,366 (44)
 Hemoglobin A1c (%) 7.8 (1.5)* 7.4 (1.4) 7.4 (1.4)
 Hemoglobin A1c (mmol/mol) 61.3 (16.0)* 56.9 (15.1) 57.2 (15.2)
 Thiazolidinedione (%) 7 (3) 126 (4) 133 (4)
 Other oral antidiabetic agents (%) 219 (92) 2,562 (90) 2,781 (90)
 Insulin (%) 4 (2) 37 (1) 41 (1.3)
 Urinary ACR (µg/mg) 30.9 (10.4, 91.1)* 12.9 (6. 2, 32.7) 13.5 (6. 2, 36.2)
 eGFR (ml/min/1.73m2) 63 (18)* 73 (16) 72 (17)
 IL-6 (pg/mL) 3.05 (2.13, 4.49)* 2.19 (1.5 7, 3.21) 2.26 (1.6 1, 3.33)
 hs-CRP (mg/L) 2.35 (1.19, 5.89)* 1.75 (0.84, 3.91) 1.80 (0.86, 4.03)
  hs-cTnT (ng/L) 12.0 (6.0, 20.0)* 5.0 (1.5, 10.0) 5.0 (1.5, 10.0)
 NT-proBNP (pg/mL) 353.0 (131.0, 819.0)* 75.0 (31.0, 172.0) 84.0 (33.0, 203.0)
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Values are mean (standard deviation) for continuous variables (except for triglycerides, urinary albumin-creatinine ratio, IL-6, hs-CRP, hs-cTnT, 
and NT-proBNP), median (interquartile range) for triglycerides, urinary albumin-creatinine ratio, IL-6, hs-CRP, hs-cTnT, and NT-proBNP, and 
number (%) for categorical variables.
Abbreviations: ACE, Angiotensin-converting enzyme; ACR, albumin-creatinine ratio; ARB, angiotensin II receptor blocker; DBP, diastolic blood 
pressure; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; hs-cTnT, high-
sensitivity cardiac troponin T; IL-6, interleukin-6; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SBP, 
systolic blood pressure.
*P <0.05 vs patients without heart failure event.
¶
Randomized BP-lowering treatment with perindopril-indapamide was not included.
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